Alterations in regional brain neurotensin concentrations produced by atypical antipsychotic drugs (Q68300523)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1674615%20AND%20SRC:MED&resulttype=core&format=json

23 September 2019

title

Alterations in regional brain neurotensin concentrations produced by atypical antipsychotic drugs (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1674615%20AND%20SRC:MED&resulttype=core&format=json

23 September 2019

1 reference

https://api.crossref.org/works/10.1016/0167-0115(91)90046-J

26 October 2022

1 reference

https://api.crossref.org/works/10.1016/0167-0115(91)90046-J

26 October 2022

1 reference

https://api.crossref.org/works/10.1016/0167-0115(91)90046-J

26 October 2022

4

C. B. Nemeroff

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1674615

26 October 2022

author name string

B. Levant

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1674615

26 October 2022

G. Bissette

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1674615

26 October 2022

E. Widerlöv

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1674615

26 October 2022

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=1674615

26 October 2022

publication date

1 February 1991

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1674615%20AND%20SRC:MED&resulttype=core&format=json

full work available at URL

23 September 2019

https://api.elsevier.com/content/article/PII:016701159190046J?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/0167-0115(91)90046-J

https://api.elsevier.com/content/article/PII:016701159190046J?httpAccept=text/plain

26 October 2022

1 reference

https://api.crossref.org/works/10.1016/0167-0115(91)90046-J

26 October 2022

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1674615%20AND%20SRC:MED&resulttype=core&format=json

23 September 2019

volume

32

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1674615%20AND%20SRC:MED&resulttype=core&format=json

23 September 2019

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1674615%20AND%20SRC:MED&resulttype=core&format=json

23 September 2019

page(s)

193-201

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1674615%20AND%20SRC:MED&resulttype=core&format=json

Occurrence of neurotensinlike immunoreactivity in subpopulations of hypothalamic, mesencephalic, and medullary catecholamine neurons

23 September 2019

cites work

2

1 reference

https://api.crossref.org/works/10.1016/0167-0115(91)90046-J

Neurotensin receptors are located on dopamine-containing neurones in rat midbrain

26 October 2022

3

1 reference

https://api.crossref.org/works/10.1016/0167-0115(91)90046-J

Neurotensin and cholecystokinin coexistence within neurons of the ventral mesencephalon: projections to forebrain

26 October 2022

4

1 reference

https://api.crossref.org/works/10.1016/0167-0115(91)90046-J

Enhancement of ethanol-induced sedation and hypothermia by centrally administered neurotensin, β-endorphin and bombesin

26 October 2022

7

1 reference

https://api.crossref.org/works/10.1016/0167-0115(91)90046-J

The effects of neuropeptides on discrete-trial conditioned avoidance responding

26 October 2022

8

1 reference

https://api.crossref.org/works/10.1016/0167-0115(91)90046-J

Neurotensin blocks certain amphetamine-induced behaviours

26 October 2022

9

1 reference

https://api.crossref.org/works/10.1016/0167-0115(91)90046-J

Subnormal CSF levels of neurotensin in a subgroup of schizophrenic patients: normalization after neuroleptic treatment

26 October 2022

10

1 reference

https://api.crossref.org/works/10.1016/0167-0115(91)90046-J

Neurotensin-like immunoreactivity in cerebrospinal fluid of patients with schizophrenia, depression, anorexia nervosa-bulimia, and premenstrual syndrome

26 October 2022

11

1 reference

https://api.crossref.org/works/10.1016/0167-0115(91)90046-J

Reduced CSF neurotensin concentration in drug-free schizophrenic patients

26 October 2022

12

1 reference

https://api.crossref.org/works/10.1016/0167-0115(91)90046-J

Increase of neurotensin content elicited by neuroleptics in nucleus accumbens

26 October 2022

13

1 reference

https://api.crossref.org/works/10.1016/0167-0115(91)90046-J

Alterations in [Met5]- and [Leu5]enkephalin and neurotensin content in basal ganglia induced by the long-term administration of dopamine agonist and antagonist drugs to rats

26 October 2022

14

1 reference

https://api.crossref.org/works/10.1016/0167-0115(91)90046-J

Effects of acute and long-term treatment with neuroleptics on regional telencephalic neurotensin levels in the male rat

26 October 2022

15

1 reference

https://api.crossref.org/works/10.1016/0167-0115(91)90046-J

Effects of short- and long-term haloperidol administration and withdrawal on regional brain cholecystokinin and neurotensin concentrations in the rat

26 October 2022

16

1 reference

https://api.crossref.org/works/10.1016/0167-0115(91)90046-J

Differential effects of antipsychotic drugs on the neurotensin concentration of discrete rat brain nuclei

26 October 2022

17

1 reference

https://api.crossref.org/works/10.1016/0167-0115(91)90046-J

Regional studies of catecholamines in the rat brain. I. The disposition of [3H]norepinephrine, [3H]dopamine and [3H]dopa in various regions of the brain

26 October 2022

21

1 reference

https://api.crossref.org/works/10.1016/0167-0115(91)90046-J

Ontogeny of brain neurotensin in the rat: a radioimmunoassay study

26 October 2022

22

1 reference

https://api.crossref.org/works/10.1016/0167-0115(91)90046-J

Controlled trial of sulpiride in chronic schizophrenic patients

26 October 2022

23

1 reference

https://api.crossref.org/works/10.1016/0167-0115(91)90046-J

Sulpiride and haloperidol in schizophrenia: a double-blind cross-over study of therapeutic effect, side effects and plasma concentrations

26 October 2022

25

1 reference

https://api.crossref.org/works/10.1016/0167-0115(91)90046-J

Changes in the limbic neurotensin systems induced by dopaminergic drugs

26 October 2022

26

1 reference

https://api.crossref.org/works/10.1016/0167-0115(91)90046-J

Role of dopamine D-1 and D-2 receptors in the regulation of neurotensin systems of the neostriatum and the nucleus accumbens

26 October 2022

27

1 reference

https://api.crossref.org/works/10.1016/0167-0115(91)90046-J

Dopamine D2 receptors exert tonic regulation over discrete neurotensin systems of the rat brain

26 October 2022

28

1 reference

https://api.crossref.org/works/10.1016/0167-0115(91)90046-J

The first clinical study of BW-234U in schizophrenia

26 October 2022

29

1 reference

https://api.crossref.org/works/10.1016/0167-0115(91)90046-J

An early Phase II clinical trial of BW234U in the treatment of acute schizophrenia in newly admitted patients

26 October 2022

31

1 reference

https://api.crossref.org/works/10.1016/0167-0115(91)90046-J

Evidence that the potential antipsychotic agent rimcazole (BW 234U) is a specific, competitive antagonist of sigma sites in brain

26 October 2022

32

1 reference

https://api.crossref.org/works/10.1016/0167-0115(91)90046-J

Novel antipsychotic drugs share high affinity for sigma receptors

26 October 2022

33

1 reference

https://api.crossref.org/works/10.1016/0167-0115(91)90046-J

Acute and subchronic effects of Rimcazole (BW 234U), a potential antipsychotic drug, on A9 and A10 dopamine neurons in the rat.

26 October 2022

34

1 reference

https://api.crossref.org/works/10.1016/0167-0115(91)90046-J

Dopamine neurochemical profile of atypical antipsychotics resembles that of D-1 antagonists.

26 October 2022

35

1 reference

https://api.crossref.org/works/10.1016/0167-0115(91)90046-J

Remoxipride in schizophrenia. A preliminary report

26 October 2022

36

1 reference

https://api.crossref.org/works/10.1016/0167-0115(91)90046-J

Antipsychotic effect of remoxipride, a new substituted benzamide with selective antidopaminergic activity

26 October 2022

37

1 reference

https://api.crossref.org/works/10.1016/0167-0115(91)90046-J

A double blind comparative study of remoxipride and thioridazine in the acute phase of schizophrenia

26 October 2022

39

1 reference

https://api.crossref.org/works/10.1016/0167-0115(91)90046-J

Differential effects of the dopamine antagonist remoxipride on apomorphine induced behaviour in the rat.

26 October 2022

41

1 reference

https://api.crossref.org/works/10.1016/0167-0115(91)90046-J

26 October 2022

Identifiers

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1674615%20AND%20SRC:MED&resulttype=core&format=json

23 September 2019

1 reference